318 related articles for article (PubMed ID: 33232908)
1. Cerebrospinal fluid lactate level in aquaporin-4 antibody positive neuromyelitis optica spectrum disorders: a hint on differential diagnosis and possible immunopathogenesis.
Wang N; Zhang SN; Xing RJ; Liu MQ; Huang CN; Jiang SM; Li T; Yang CS; Yang L; Zhang LJ
Mult Scler Relat Disord; 2021 Jan; 47():102629. PubMed ID: 33232908
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures.
Jarius S; Paul F; Franciotta D; Ruprecht K; Ringelstein M; Bergamaschi R; Rommer P; Kleiter I; Stich O; Reuss R; Rauer S; Zettl UK; Wandinger KP; Melms A; Aktas O; Kristoferitsch W; Wildemann B
J Neurol Sci; 2011 Jul; 306(1-2):82-90. PubMed ID: 21550068
[TBL] [Abstract][Full Text] [Related]
3. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.
Jarius S; Aktas O; Ayzenberg I; Bellmann-Strobl J; Berthele A; Giglhuber K; Häußler V; Havla J; Hellwig K; Hümmert MW; Kleiter I; Klotz L; Krumbholz M; Kümpfel T; Paul F; Ringelstein M; Ruprecht K; Senel M; Stellmann JP; Bergh FT; Tumani H; Wildemann B; Trebst C;
J Neurol; 2023 Jul; 270(7):3341-3368. PubMed ID: 37022481
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance.
Jarius S; Franciotta D; Paul F; Ruprecht K; Bergamaschi R; Rommer PS; Reuss R; Probst C; Kristoferitsch W; Wandinger KP; Wildemann B
J Neuroinflammation; 2010 Sep; 7():52. PubMed ID: 20825655
[TBL] [Abstract][Full Text] [Related]
5. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
[TBL] [Abstract][Full Text] [Related]
6. Clinical Features of Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders.
Chen H; Liu SM; Zhang XX; Liu YO; Li SZ; Liu Z; Dong HQ
Chin Med J (Engl); 2016 Sep; 129(17):2079-84. PubMed ID: 27569235
[TBL] [Abstract][Full Text] [Related]
7. Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders.
Kim SM; Waters P; Woodhall M; Kim JY; Kim JE; Yang JW; Kim JS; Sung JJ; Park KS; Lee KW
Mult Scler; 2013 Jul; 19(8):1060-7. PubMed ID: 23329699
[TBL] [Abstract][Full Text] [Related]
8. Pruritus in neuromyelitis optica spectrum disorders and multiple sclerosis.
He M; Wu L; Huang D; Yau V; Yu S
J Clin Neurosci; 2020 Sep; 79():108-112. PubMed ID: 33070876
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the binding pattern of human aquaporin-4 autoantibodies in patients with neuromyelitis optica spectrum disorders.
Tuller F; Holzer H; Schanda K; Aboulenein-Djamshidian F; Höftberger R; Khalil M; Seifert-Held T; Leutmezer F; Berger T; Reindl M
J Neuroinflammation; 2016 Jul; 13(1):176. PubMed ID: 27371173
[TBL] [Abstract][Full Text] [Related]
10. Systemic inflammation response index is a useful indicator in distinguishing MOGAD from AQP4-IgG-positive NMOSD.
Wang L; Xia R; Li X; Shan J; Wang S
Front Immunol; 2023; 14():1293100. PubMed ID: 38259484
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia.
Fabis-Pedrini MJ; Bundell C; Wee CK; Lucas M; McLean-Tooke A; Mastaglia FL; Carroll WM; Kermode AG
J Neuroimmunol; 2018 Nov; 324():76-80. PubMed ID: 30248527
[TBL] [Abstract][Full Text] [Related]
12. The influence of smoking on the pattern of disability and relapse risk in AQP4-positive Neuromyelitis Optica Spectrum Disorder, MOG-Ab Disease and Multiple Sclerosis.
Messina S; Mariano R; Geraldes R; Kim SH; Satukijcha C; Vecchio D; Chua YY; Taylor J; George N; Cavey A; Diaz AR; Reeve S; Everett R; De Luca G; Leite MI; Kim HJ; Palace J
Mult Scler Relat Disord; 2021 Apr; 49():102773. PubMed ID: 33540279
[TBL] [Abstract][Full Text] [Related]
13. Overlap syndrome of anti-aquaporin-4 positive neuromyelitis optica spectrum disorder and systemic lupus erythematosus: A systematic review of individual patient data.
Kopp CR; Prasad CB; Naidu S; Sharma V; Misra DP; Agarwal V; Sharma A
Lupus; 2023 Sep; 32(10):1164-1172. PubMed ID: 37487596
[TBL] [Abstract][Full Text] [Related]
14. Quantitative brain lesion distribution may distinguish MOG-ab and AQP4-ab neuromyelitis optica spectrum disorders.
Yang L; Li H; Xia W; Quan C; Zhou L; Geng D; Li Y
Eur Radiol; 2020 Mar; 30(3):1470-1479. PubMed ID: 31748853
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of intereye difference metrics for optic neuritis in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorders.
Oertel FC; Zimmermann HG; Motamedi S; Chien C; Aktas O; Albrecht P; Ringelstein M; Dcunha A; Pandit L; Martinez-Lapiscina EH; Sanchez-Dalmau B; Villoslada P; Palace J; Roca-Fernández A; Leite MI; Sharma SM; Leocani L; Pisa M; Radaelli M; Lana-Peixoto MA; Fontenelle MA; Havla J; Ashtari F; Kafieh R; Dehghani A; Pourazizi M; Marignier R; Cobo-Calvo A; Asgari N; Jacob A; Huda S; Mao-Draayer Y; Green AJ; Kenney R; Yeaman MR; Smith TJ; Cook L; Brandt AU; Paul F; Petzold A
J Neurol Neurosurg Psychiatry; 2023 Jul; 94(7):560-566. PubMed ID: 36810323
[TBL] [Abstract][Full Text] [Related]
16. [Actual issues of serum aquaporin-4 autoantibodies evaluation in the diagnostics of neuromyelitis optica spectrum disorders].
Krasnov VS; Totolyan NA; Nazarov VD; Mazing AV; Makshakov GS; Lapin SV; Evdoshenko EP; Skoromets AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(7. Vyp. 2):24-31. PubMed ID: 32844626
[TBL] [Abstract][Full Text] [Related]
17. [Clinical presentations of neuromyelitis optica spectrum disorders with ultra-longitudinally extensive transverse myelitis].
Huang X; Xu FF; Qian HR; Lei X; Qi XK; Xia DY
Zhonghua Yi Xue Za Zhi; 2018 Jun; 98(21):1658-1663. PubMed ID: 29925142
[No Abstract] [Full Text] [Related]
18. CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications.
Kaneko K; Sato DK; Nakashima I; Ogawa R; Akaishi T; Takai Y; Nishiyama S; Takahashi T; Misu T; Kuroda H; Tanaka S; Nomura K; Hashimoto Y; Callegaro D; Steinman L; Fujihara K; Aoki M
J Neurol Neurosurg Psychiatry; 2018 Sep; 89(9):927-936. PubMed ID: 29875186
[TBL] [Abstract][Full Text] [Related]
19. Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease.
Juryńczyk M; Tackley G; Kong Y; Geraldes R; Matthews L; Woodhall M; Waters P; Kuker W; Craner M; Weir A; DeLuca GC; Kremer S; Leite MI; Vincent A; Jacob A; de Sèze J; Palace J
J Neurol Neurosurg Psychiatry; 2017 Feb; 88(2):132-136. PubMed ID: 27951522
[TBL] [Abstract][Full Text] [Related]
20. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
